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Abstract
The therapeutic replacement of diseased tubular tissue is hindered by the availability and suitability of current donor, autol-
ogous and synthetically derived protheses. Artificially created, tissue engineered, constructs have the potential to alleviate
these concerns with reduced autoimmune response, high anatomical accuracy, long-term patency and growth potential. The
advent of 3D bioprinting technology has further supplemented the technological toolbox, opening up new biofabrication
research opportunities and expanding the therapeutic potential of the field. In this review, we highlight the challenges facing
those seeking to create artificial tubular tissue with its associated complex macro- and microscopic architecture. Current
biofabrication approaches, including 3D printing techniques, are reviewed and future directions suggested.
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Introduction
Tubular tissue structures are ubiquitous throughout the body
and its organ systems, with notable examples found in the
vasculature (arteries, veins, capillaries), respiratory, (oesoph-
agus, trachea), urinary (ureter, urethra, bladder), and gas-
trointestinal systems [1]. Whilst shape is the common feature
amongst these cited examples, there is considerable variation
in scale, tissue architecture and function that are ultimately
imbued by the arrangement of different cell types and their
surrounding extra cellular matrix (ECM). In a similar fash-
ion to other organ systems, tubular tissue is prone to disease
and malfunction, often requiring therapeutic intervention in
the form of replacement with a synthetic prothesis, donor
tissue or an autologous implant [2,3]. However, these proce-
dures currently have a number of limitations. There remains
a disparity between the high demand for replacement donor
tissue and the paucity of suitable donors [4,5] and adequate
autologous tissue may not be always be available [6–9]. Syn-
thetic polymer, prostheses, whilst readily available, generally
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struggle to match demanding anatomical and mechanical
requirements, have limited growth potential and have per-
sistent concerns around their long-term patency [6,8,10].
Tissue engineering has emerged as one of the health-
care technologies of the future and offers a potential route
to address the current therapeutic challenges by allowing
researchers and clinicians to create patient-specific devices
that more accurately represent the in-vivo tissue being
replaced or augmented [9,11]. The advent of bioadditive
manufacturing in recent years has further added to the “tech-
nological toolbox” that is available to those engaged in
tubular tissue engineering, thus opening up a plethora of clin-
ically driven research opportunities [12]. Specifically, it has
enabled researchers and clinicians alike to consider the pos-
sibility of creating prostheses that closely mimic the native
architecture of the patient’s anatomy at both a macro- and
microscopic level [13–15]. It is therefore envisaged that such
artificial devices, created in the laboratory, can be bespoke to
the therapeutic and anatomical requirements of the patient,
thus improving clinical outcomes. In this regard, tissue engi-
neering, achieved through additive biomanufacturing, can be
considered part of the wider healthcare trend towards per-
sonalised medicine. In addition to their use as prostheses,
accurate anatomical tubular organ reconstructions have also
recently been proposed as a method for improved consulta-
tions between surgeons and their patients, in clinical training
scenarios and planning complex surgical operations [16].
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Research using 3D biofabrication methods to create vas-
culature predominates over other tubular tissue types. Vascu-
lature replacement or augmentation is utilised to treat a range
of conditions, including aortic aneurysm repair and congeni-
tal defects. Vascular networks are also critical for researchers
seeking to create any large artificial organ system, allowing
the nutrient and gas exchange processes that are necessary in
an in-vivo environment for tissue survival [17,18]. Within the
domain of vascular tissue engineering, the challenge resides
in creating the distinct endothelial, medial and adventitial
layers that are themselves composed of smaller concentric
rings of cells and ECM. The task is further complicated by
the high level of heterogeneity across the vascular system,
not only in terms of the structural arrangement and ratios
of these layers but also in the phenotype of the constituent
cells (Aird 2007). The target for research groups is to cre-
ate anatomically accurate, branched, vasculature that has the
representative thin collagen and elastin layers, containing the
requisite cells in sufficient numbers and alignment [10,19].
There is also need for the development of tubular struc-
tures in other areas of healthcare. Examples include oesoph-
agus and trachea repair following disease, where the airways
require reconstruction. Artificial protheses created in the lab-
oratory could enable the augmentation or replacement of
ineffectual or collapsed airways, replacing current stenting
techniques. The capability to match the device to the complex
anatomical geometry seen in the tracheobronchial tree is a
distinct advantage for bioadditive manufacturing techniques
over the use of standardised prostheses [20,21]. Whilst indi-
vidual studies are often focussed on the creation of a specific
tubular tissue type, the methodologies that they employ could
be applied to other organs requiring transplantation. There-
fore, whilst many of the methods described in this review
refer to studies aiming to recreate vascular tissue, the princi-
ples and techniques used can be applicable to the creation of
other tubular tissue structures found throughout the body.
In this article, we aim to review current 3D biofab-
rication methodologies and techniques used for tubular
organ construction and provide an overview of 3D printing
technologies and materials that are of relevance in the devel-
opment of tubular structures.
Current tissue engineering approaches
One method that has attracted widespread attention for tissue
engineering tubular organs is the use of a scaffold material
that can then be subsequently populated with the patient’s
own cells. The intention is to create a device that has the requi-
site 3D ECM and patient-specific cell types needed to create
functional tissue that has a reduced risk of autoimmune rejec-
tion (Fig. 1). The use of this process has been explored for
vascular tubes using a range of sources for the scaffold such as
synthetic polymers [22,23], natural polymers [24,25], decel-
lularised animal [26] and human tissue [27]. For an extensive
review on scaffold seeding, materials and methods for vas-
cular tissue engineering refer to Pashneh-Tala et al. [2]. The
decellularisation and recellularisation approach has also been
attempted for bile duct replacement in a murine model [28].
Tracheal replacement too has utilised this method, although
simple tubular construction is not sufficient to accurately
represent the in-vivo tissue, with it being comprised of mul-
tiple C-shaped cartilage sections [21]. However, high profile
failures have limited progress in this area, with cellular infil-
tration and artificial organ acceptance shown to be not as
successful as previously hoped [29].
Beyond scaffold seeding, other manufacturing techniques
to create tubular organ structures have been reported and
refined since the 1980s. Weinberg and Bell pioneered the
tissue-engineered blood vessel in 1986, by casting collagen
containing smooth muscle cells and adventitial fibroblasts
into tubes (Fig. 2a). Their devices, however, required the
integration of a synthetic Dacron mesh to increase the burst
pressure, a deficiency the authors attributed to the ECM com-
position and low cell densities [30]. A further step forward
in the field was developed by L’Heureux et al., who used
a process that was devoid of any synthetic or exogenous
biological material by inducing the excretion of collagen in
cultured cell sheets of smooth muscle cells and fibroblasts
(Fig. 2b). Layers of these sheets were then wrapped around a
mandrel and further cultured as tubes to create a final artery
mimic containing distinct endothelial, medial and adventi-
tial layers [31]. An acellular approach to sheet assembly has
been shown by Kumar et al. (Fig. 2d). The group created a
collagen and elastin sheet that was then rolled as a tube to
create an acellular version containing the distinct elastin and
collagen layers that are observed in native arterial tissue and
deemed essential for mechanical strength. Compared against
traditional rigid polymer conduits, the device had compa-
rable burst pressures and reduced adherence of platelets, a
pro-thombotic mediator [32]. This rolling methodology was
further developed by Othman et al., using an automated plat-
form to create tubular architectures with desired scales and
dimensions at cell resolutions. By repeating the rolling pro-
gramme, three-dimensional tubular structures with multiple
layers, cell types and materials could be constructed. The fab-
ricated tissues could be directly transferred into a perfusion
bioreactor without further manipulation. This strategy pro-
vides a convenient method to fabricate multiple biomaterial
types and a route to high volume device production [33].
A simplified, efficient method of tubular tissue construc-
tion is the use of a rod that can be alternately dipped into
a cell-laden hydrogel and a cross-linking agent (Fig. 2c).
Repeated dipping operations form multiple layers that can
potentially be made from different hydrogels. The method
was used by Tabriz et al., to create layers containing viable
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Fig. 1 Tissue engineering process for tubular organs using decellularised animal donor tissue
human embryonic kidney and mouse fibroblast cells. The
thickness of each layer was determined to be in the range
126–220 µm with this being dictated by the wettability of
the surface being coated, and the composition of the hydrogel
adhered to the surface prior to the cross-linking phase. The
authors conclude that their approach could be adapted for use
in a range of tubular tissue types [34]. This methodology was
further developed by Wilkens et al., who introduced motors
to rotate and the dip rods. A major benefit of this approach
was a level of control over the thickness of the layers. The
smallest layer attained was ≈ 25 µm and is of significance
as this matches the medial collagen and smooth muscle cell
layers observed in native arterial tissue [35].
Following assembly of tubular structures, a number of
research groups have highlighted the influence that the post
manufacture culture conditions can have on an artificially
assembled construct. The most cited example is the migration
and alignment of cells in vascular tissue, with created tubu-
lar organs cultured in bespoke bioreactors with integrated
flow systems. It has been observed that exposing artifi-
cially engineered tissue to fluid flow induced shear stress,
or mechanical stretching, can cause not only the cellular ele-
ments to migrate and align in a direction perpendicular to flow
direction [7,23,25,36] but also ECM components too [37].
The postassembly culture stage can therefore be exploited to
remodel and mature artificial tubular organs towards a more
representative in-vivo state than is feasible using the initial
bioadditive assembly techniques.
Although the progress in methodology and techniques for
constructing tubular organs has been made, the fabricated
structures are still relatively simple in comparison with the
native tissue they intend to mimic. This is especially true in
regard to the control the processes have over the microscale
organisation of cell and extra cellular matrix layers and in par-
ticular the complex anatomical architecture of tubular organ
networks, such as multiple bifurcations, typically observed
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Fig. 2 Tissue engineering
variants and methods for
manufacture of tubular organs. a
Cell-laden hydrogel casting with
synthetic polymer mesh [30]. b
Cell and extracellular sheet
matrix assembly [31]. c Rod dip
coating [34,35]. d Sheet
rolling [32,33]
Ascorbic 
acid
Cell laden hydrogel poured into thin walled 
casting tube and removed once gelled
Addition of synthetic meshes and/or further cast hydrogels can 
improve final tubular structures mechanical properties
Hydrogel casting
Cell sheet assembly
Smooth muscle cells 
grown as a monolayer
Cells induced to express 
extracellular matrix proteins 
through the addition of 
growth factors
Cell and extracellular matrix sheet 
rolled around a mandrel to create 
tubular structure
Additional sheets added containing 
adventitial fibroblasts to create arterial layersDip coating
Repeated operations into different hydrogels 
can build up a tube composed of multiple 
distinct layers
Alternate dipping of rod into hydrogel and crosslinking agent creates thin 
layers on the surface
Sheet rolling
Layers with different properties and cell types are 
established
Rolling of the sheet around a mandrel multiple times 
creates a tubular structure
(a)
(b)
(c)
(d)
Cell laden hydrogel Cross linking agent
in native tubular structures. More sophisticated techniques
that enable researchers to fabricate complex, multi-layered
structures with precise spatial controls are therefore needed.
3D bioprinting
3D bioprinting [38,39] has emerged as a one such technol-
ogy that has the potential to fabricate complex structures
composed of cells and an associated support matrix and
can be used to create tubular organ structures. The possible
modalities of 3D bioprinting can be categorised into three
main categories, namely extrusion-based bioprinting (EBB),
droplet-based bioprinting (DBB) and laser-assisted bioprint-
ing (LAB) [40].
Extrusion-based bioprinting involves the positive dis-
placement of material by an applied force, which can be
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either pneumatic, mechanical or solenoid-assisted. Usually
non-Newtonian fluids are utilised, whereby viscosity and
shear response are important; thixotropic substances are the
most desirable here. It is imperative that extrudable materials
can easily overcome surface tension and are capable of rapid
gelation for shape retention without unwanted flow on print
beds. Additionally, the substrate should have surface rough-
ness with low wettability to allow prints to adhere to surfaces
with shape retention. EBB is the most economical of the three
bioprinting modalities, and there is a wide range of printable
viscosities (30–6 × 107 mPa s) [41]. Printing resolution is
a major technical challenge of extrusion-based bioprinting,
as is the minimisation of cellular shear stress upon nozzle
ejection, both of which are not mutually exclusive [42].
Secondly, droplet-based bioprinting makes use of energy
sources such as electricity, acoustics and heat to create bio-
ink droplets. There are four possible methodologies when
applying DBB: inkjet printing (electrostatic/piezoelectric/
thermal), electro-hydrodynamic jetting, acoustic droplet
ejection and micro-valve printing. Bio-inks in DBB should
have low viscosity and have a non-fibrous structure, to allow
easy flow through tubing and nozzles, to avoid clogging.
The need for low viscosity is, however, problematic as it
is challenging for low-viscosity materials to change form
into a solid-state structure. Bio-inks must also be rheopec-
tic in nature to allow droplets to form upon ejection from
nozzles. Further, substrates must have adequate surface ten-
sion to travel through cartridges without leakage, which
can lead to print head flooding and nozzle tip wetting.
Droplets should solidify upon contacting print bed surfaces
to avoid unwanted material flow. There are many drawbacks
to using DBB, such as low cell concentrations, thermal and
mechanical stress to cells and cell encapsulation impreci-
sion [43].
Laser-assisted bioprinting makes use of laser energy
to print liquids onto supports substrates at high preci-
sion, with no need for nozzles thus avoiding the clog-
ging issues associated with EBB and DBB. LAB can be
achieved by two separate means—cell-transfer-based and
photo-polymerisation LAB. Cell-transfer-based operations
can involve laser-guided direct writing [44] or laser-induced
forward transfer (LIFT) [45] whereby bio-ink is ejected from
a reservoir to the substrate by laser, thus allowing a jet
to be produced. The bio-ink in cell-transfer laser systems
should be capable of adhering to substrates whilst possess-
ing low surface tension to allow uniform spreading on the
surface without dripping. In addition, the bio-ink should be
capable of transforming thermal energy into kinetic energy
with ease whilst also displaying high viscoelasticity and
swift gelation to allow jet formation. Processes involving
photo-polymerisation include stereolithography (SLA) [46]
and two-photon polymerisation (2PP) [47], in which the
laser beam selectively causes the solidification of a photo-
curable bio-ink via polymerisation. The use of non-toxic,
water-soluble photo-initiators and light absorbers allows
photo-polymerisation to occur, resulting in the manufac-
ture of tissue constructs with uniform layer thickness. The
demands on bio-inks here include high mechanical strength
and the ability to maintain the even distribution of cells in
the precursor solution [48].
3D bioprinting for tubular tissue
engineering
A range of approaches have used 3D printing technology to
create tubular organ structures; however no methodology has
emerged a forerunner. Such variation is indicative of both the
nascent nature of the field and of the variety seen in the native
tubular tissue that is being mimicked.
The use of 3D printers to arrange annuli or a continu-
ous spiral of material that when layered in the vertical plane
progressively fabricates a tubular structure (Fig. 3a). The key
disadvantage is the substrate layers must be structurally rigid
enough to support the both the upper layers and the addi-
tion of new material. This places mechanical constraints on
the type of bio-inks that can be used and ultimately limits
the dimensional range that can be created. Furthermore, the
creation of multiple concentric layers composed of different
hydrogel and cell types seen in native tubular tissue is diffi-
cult to achieve. Consequently, printed tubular tissues created
using this method are usually composed of a single homoge-
nous material. However, Tan and Yeong were able to induce
a variation in the properties of the tube wall through the addi-
tion of a cross-linking agent to core of the tube and through
careful optimisation of the viscous properties of the alginate
hydrogel, print self-supporting structures with clinically rel-
evant dimensions [49] (Fig. 3a).
Fugitive inks have been utilised to create complex tubular
anatomical shapes as a means of overcoming the problems
associated with viscous bio-inks that are unable to provide the
structural integrity needed during the printing process. The
process involves printing self-supporting structures using a
fugitive ink, exploiting its rigid mechanical properties. This
structure can then be embedded in a second hydrogel that con-
tains the desired cells for the tissue type to be created. The
fugitive ink is then liquified and removed through a variation
in temperature or simply dissolved (Fig. 3b). The relevance of
this technique to tubular organ manufacture is that the fugitive
ink can be printed as a network of interlinked cylinders, which
can subsequently be endothelialised to create a tubular vas-
cular network capable of allowing nutrient perfusion to the
surrounding tissue [50–52] and angiogenic sprouting [53]. In
principle, this technique represents an innovative bioprinting
variation on the lost wax casting method historically used to
produce metallic components.
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(d) Kenzan method
(c) FRESH  printing
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Fig. 3 3D printing variants and methods for bioadditive manufacture of
tubular organs. a Concentric ring assembly [49]. b Vasculature network
creation via fugitive inks [50,51,53]. c Freeform reversible embedding
of suspended hydrogels (FRESH) printing [54,55]. d Kenzan printing
of cell spheroids onto needles [56,57]. e Coaxial tube formation from a
modified nozzle [59–61]. f Rod support printing (Sichuan Revotek cor-
poration, unpublished). g Coaxial extrusion onto rotating glass rod [62]
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Freeform reversible embedding of suspended hydrogels
(FRESH) is a novel approach that could be considered as the
inverse of the fugitive ink method developed by Kolesky and
others. The technique prints hydrogels directly at 20 ◦C into
a support bath containing a secondary hydrogel, also referred
to as a fugitive support gel. This has the effect of providing
mechanical support for the printed material. Elevating the
temperature to 37 ◦C melts the support bath hydrogel, leav-
ing a self-supported, printed structure behind [54] (Fig. 3c).
The method has been employed to print a range of complex
tubular structures, including helical coils and bifurcated ves-
sels [55].
An innovative method of tubular organ assembly has
been demonstrated by Itoh et al. using metallic needles
in a circular array as a temporary scaffold for supporting
cell spheroids. Termed the Kenzan method, the group used
the needles to support smooth muscle cell and fibroblast
spheroids (650 µm, diameter) that then, after a period of cul-
ture in a bioreactor, fused permitting removal of the support
needles to create a rigid tubular structure [56,57] (Fig. 3d).
As an alternative to spheroids, Norotte et al. assembled high
density extruded cellular cylinders, supported by acellular
agarose rods, into tubular tissue, with this process achieving
a reduction in printing times when compared to individual
spheroid assembly [58].
The process of coaxial printing has also been employed
by several research groups to create microtubular constructs.
A nozzle is modified to include inner and outer cores that
allow gels and bio-inks to be extruded into tubes, with the
final size determinised by the dimensions of the nozzle. By
extruding a cross-linking agent as the inner core, the outer
shell can be rapidly cross linked to form a self-supporting hol-
low tube [59,60]. Jia et al. also included an additional outer
shell to their nozzle to allow cross-linking perfusion from
two directions [61]. Gao et al further extended the principle
to print two separate bio-inks of an endothelial progenitor
cell-laden alginate surrounding a more rigid sacrificial sup-
porting core, containing a cross-linking agent [62] (Fig. 3e).
This method permits a longer cross-linking time, allowing a
greater selection of bio-inks to be considered. A key advan-
tage of coaxial printing is its ease of manufacture, creating
very long conduits in a minimal amount time. Deficiencies
are the difficulty in creating complex, bifurcated, anatomi-
cal structures, and the creation of multiple microscale layers
seen in many native tubular organ structures.
Direct printing of cell-laden gels onto a rotating rod can
serve as a method for creating hollow tubes, and this additive
manufacturing technique can be considered as the inverse
of traditional lathe machining practices. The rod provides
a temporary support for the hydrogel and is removed once
the structure is deemed to be self-supporting. The company
Sichuan Revotek claim to have utilised this method in com-
bination with an adipose stem cell-laden hydrogel to create
Table 1 Ideal requirements of engineered tubular tissues adapted from
Catto et al. [65]
Biocompatibility Non-toxic
Non-immunogenic
Not susceptible to infection
Growth potential for paediatric
patients
Non-cytotoxic degradation products
Mechanical properties Mechanical properties similar to native
vessel to allow structural stability
Adequate suture
retention/neighbouring vessel
integration
Processability Low manufacturing costs
Readily available with many different
sizes
Sterilisable
Easy storage
artery mimics that were subsequently transplanted into mon-
keys, although no data has yet been published (Fig. 3f).
A variant of rod printing combines it with the previously
described coaxial printing. Hollow microtubes are printed
onto a rotating glass rod to create a multifluidic tubular organ
with a micro- and macrochannel [62] (Fig. 3g).
Bio-inks for 3D printing tubular organs
As previously indicated the selection of a suitable bio-ink is
critical to any 3D printing process. A bio-ink is a formulation
of material(s) and biological molecules or cells processed
using bioprinting technologies [63]. Typically, these are com-
binations of hydrogels and living cells that are implemented
into 3D bioprinting hardware capable of creating cell-laden
structures of pre-defined geometries [15,34]. A key challenge
for researchers aiming to 3D print tubular, and other organ,
structures is the formulation of bio-inks whose properties,
in their final embodiment, align as closely possible with the
tissue type being fabricated. The key structural component
of a bio-ink is the hydrogel, a polymer-based structures of
hydrophilic nature, with the ability to swell in high water
content surroundings. Hydrogels therefore provide the three-
dimensional environment required for cells to adhere and
grow [64].
Table 1 presents a summary of the ideal requirements of
engineered tissues for one tubular organ type, vascular grafts
and has been produced by the adaption of a table presented
by Catto et al. [65] for the requirements of an ideal tissue
engineered.
A further consideration is that the hydrogel may be
required to degrade at an equal rate to extracellular matrix
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Table 2 Hydrogel requirements for 3D bioprinting using bio-inks
3D Structure High porosity, integrin-activated, stiffness
Viscosity Shear stress:
shear-thinning/shear-thickening
Surface tension Retention inside nozzle until printing.
Limited spreading, spraying, spilling
upon printing
Gelation Rapid gelation via cross-linking, shape
retention
Physical properties Molecular mass, concentration,
composition
Cell integration Minimal viability loss during printing due
to nozzle shear stress. Cell
differentiation, proliferation, growth,
tissue formation
secretion by cells, ensuring the structure can be maintained
during host integration [61,66]. In addition, hydrogel degra-
dation products must not have a considerably deleterious
effect on fabricated organs or the surrounding in vivo envi-
ronment, in order to avoid immunological issues. A summary
of the requirements of hydrogels for 3D bioprinting using
bio-inks can be seen in Table 2.
Hydrogels can be broadly classified into two categories:
natural and synthetic. Generally, natural hydrogel materi-
als offer high biocompatibility and biodegradability whilst
innately having the structure to support cell migration, adhe-
sion, maintenance and growth with the major drawback
of lacking the mechanical strength to support their own
weight. Conversely, synthetic materials possess the mechan-
ical strength to retain shape and structure but generally suffer
from poor biocompatibility and are non-biodegradable.
Natural materials
Of the many natural materials used within hydrogels and
bio-inks, alginate is one of the predominant used in bio-
printing. Alginate is a natural polysaccharide derived from
the cell wall of brown algae, a linear copolymer consisting
of guluronic acid and mannuronic acid, in differing ratios
depending on batch composition [67]. Alginate is favoured
in bioprinting environments due to its ability to form bio-
compatible, biodegradable and printable hydrogel at room
temperature in addition to its low cost. However, alginate
is known to be bio-inert and suffers from low cellular adhe-
sion and slow degradation kinetics, resulting in unfavourable
cellular proliferation and differentiation [68].
Alginate is particularly suited to extrusion-based bioprint-
ing due to the ease of cross-linking and the wide range of
possible concentrations giving rise to mechanically stable
structures. Alginate can be extruded in either precursor or
pre-crosslinked form, where alginate is mixed with a low con-
centration of cross-linker to improve printability [69]. Printed
alginate can be strengthened further by the addition of cross-
linker (typically 100–200 mM CaCl2). These properties have
led to the use of alginate-based bio-inks by different research
groups for the creation of cell-encapsulated printable tubular
structures. Tan and Yeong vertically printed tubular con-
structs [49], and Gao et al. and Gao et al. extruded alginate to
fabricate the previously described coaxially printed vascular
structures [62,70].
Collagen too can be used as the hydrogel component of
a bio-ink. Collagen is a protein that exists in a triple-helix
arrangement of polypeptides [71] and is the most abundant
structural protein in the human body, primarily located in the
extracellular matrix (ECM) of connective tissues. Collagen
exists in many types, distinguished by the three-dimensional
structures that are formed. It should be noted that the type
of ECM collagen can vary even within the same tissue, with
collagen I, III and IV present in the vasculature [72].
The fibrillar Type I collagen is the most commonly used
type in 3D bioprinting. Collagen has the ability to allow
cell adhesion and enhance cell attachment and proliferation
due to the presence of RGD (asparagine–glycine–aspartic
acid) residues, allowing integrin binding [13]. Collagen
is a biodegradable protein with low toxicity and minimal
cross-species immunological reactions. All of these factors
promote collagen as a suitable material to be used in 3D
bioprinted constructs as a scaffold material [73].
As collagen is of low mechanical strength, it is mainly inte-
grated into the bioprinting of tubular structures as a medium
for cell encapsulation, similar to alginate, but with the afore-
mentioned enhanced biocompatibility. A key advantage of
collagen is that the bio-ink can be tailored contain the ECM
components and cells and that are present in the tissue being
mimicked, an approach used in casting methods of Weinberg
and Bell [30].
Other natural materials that are commonly used in bio-
printing include agarose, fibrin, gelatin, and hyaluronic acid,
amongst others.
Synthetic materials
Of all synthetic hydrogel constituents, pluronic F-127 is
amongst the most commonly used, largely in part to its
approved use in humans by the FDA [74]. Chemically,
pluronics are triblock copolymers consisting of two
hydrophilic polyethylene glycol (PEG) blocks at either end of
a hydrophobic polypropylene glycol (PPG) block. Pluronic
is a trademark name for poloxamers, of which there are many
types, named by a letter (L for liquid, P for paste, F for
flake/solid) followed by a two- or three-digit numerical value,
representative of chain length and molecular weight.
Pluronic F-127 forms micelles in solution once a cer-
tain concentration is reached, known as the critical micelle
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concentration (CMC). Upon reaching the CMC, the solu-
tion transitions to a gel phase, however, this gel is of low
mechanical strength. The concentration of pluronic F-127
can be controlled in such a way as to manipulate the gelation
temperature and hence printability during extrusion-based
bioprinting. A minimal concentration of 15 wt% [75] is
required for gelation of pluronic F-127; typically a concen-
tration of 25–40% w/v is utilised. This allows the storage of
pluronic F-127 as a liquid at sub-room temperature, gel print-
ing at room temperature and storage of printed scaffolds up
to incubation temperature. Pluronic scaffolds can be thermo-
degraded back to liquid state and washed away simply by
lowering the temperature below the lower critical gelation
temperature (LCGT) [76].
In addition, pluronics have been used in cell-printing oper-
ations, partially due to their low toxicity [77], and it has
been shown that they can be printed with no excessively
detrimental shear stress effects on encapsulated cells [78].
The aforementioned factors all indicate that pluronic F-
127 is a suitable material for 3D bioprinting. However, it
should be noted that the synthetic nature of pluronics nat-
urally deems them non-bioactive, therefore deeming them
unusable in environments where long-term cell viability
is required [79]. This is in addition to the tendency for
pluronic to dissolve in aqueous environments, leading to
incompatibility with long-term cell culture conditions where
scaffold structural support is essential. Gao et al imple-
mented pluronic F-127 (40% w/v) in a core-shell coaxial
printing configuration, with the aim of creating biological
blood vessels (BBV). Recently, the Suntornnond group com-
bined pluronic F-127 with gelatin methacrylate (GelMA) to
create a biocompatible hydrogel with the ability to maintain
shape integrity and capable of producing perfusable com-
plex vascular-like structures upon printing. Printed hollow
quadfurcated tubular structures supported human umbilical
vein endothelial cell (HUVEC) proliferation and differenti-
ation [80].
DNA-based hydrogel is also a novel and outstanding bio-
ink for 3D printing. Compared to other synthetic materials,
DNA-based hydrogels have many excellent characteristics,
such as responsiveness, biocompatibility, shear-thinning and
fast self-healing properties. Liu and Shu et al. achieved
in situ multilayer three-dimensional living cell bioprinting
using DNA-polypeptide hybrid supramolecular hydrogel.
In this method, two bio-inks were co-printed through the
dual-nozzle printer. One is the DNA-polypeptide solution
mixed with living cells, and the other is the complementary
DNA solution. It is noteworthy that the printed structures
are intact and uniform without gaps between two layers,
which is attributed to the self-healing property of the hydro-
gels. Moreover, the cells in the printed hydrogels have high
viability reaching 98.8% [81]. Later, Liu et al. also devel-
oped a new “brick-to-wall” strategy to construct tissue-like
structure based on pure DNA hydrogels. Compared to tradi-
tional supramolecular hydrogels, this pure DNA hydrogel
is fully composed of stiff DNA duplexes and there is no
chain entanglement in the network, resulting in the absence
of the pores smaller than a certain size. It therefore has
good permeability allowing growth factors and proteins to
diffuse into the DNA hydrogels’ internal network. Exploit-
ing this advantage, the group encapsulated different cells
into separate hydrogel bricks and observed cell migration
between them [82]. Although supermolecular DNA-based
hydrogels [83–85] have yet to be explored in the context
of tubular organ manufacture, their mechanical strength and
capacity to form multiple layers, observed in tubular tissue,
makes them a promising material for the future.
Future challenges and prospects
If biofabricated tubular organs are to usurp current syn-
thetic, donor and autologous implants, they will be required
to closely match native human tissue in terms of anatom-
ical accuracy, environmental responsiveness, mechanical
properties, autoimmune acceptance, long-term patency and
ultimately functionality. It is accepted that in attempting to
attain this objective researchers should attempt to mimic
healthy tissue architecture on the macro-, micro- and poten-
tially nanoscales [6,19,86]. This represents a considerable
technological challenge, and the complex nature of native tis-
sue means that even the most innovative current techniques
show promise they are only able to offer approximations
of the healthy tissue they are intended to replace. Although
the advent of new additive manufacturing technologies has
enabled researchers to progress considerably over the pre-
vious decade, there still remains a large gap in terms of
functionality between those devices created in the laboratory
and the stringent clinical demands of an implanted protheses.
Furthermore, in common with other new medical technolo-
gies a clear regulatory structure offering a route to market
has yet to emerge [87,88]. A further consideration is that the
clinical needs of multiple patients may require bespoke 3D
fabricated tissue urgently at the same time, thus placing strin-
gent timescales and speed requirements on any production
process [9]. The integration of automation into the process
of tubular organ fabrication has the potential to address these
manufacturing requirements [33].
Whilst the challenges in transferring from the laboratory
bench to clinical use remains high, we predict that 3D bio-
fabrication will have a crucial role in the future therapeutic
treatment of tubular tissue disease and malfunction. The
inherent advantage of using 3D bioprinting to create tubu-
lar organs is the capability to create the complex anatomical
features seen in many tubular organ structures through-
out the body. This has been demonstrated in the intricate
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perfusable vascular networks created by vasculature embed-
ding and FRESH printing [50,52,53,55]. Progress has also
been facilitated by the growing array of bio-inks available
to researchers, with developments in DNA-based hydrogels
showing potential for use in tubular organ construction [82].
However, the microscale arrangement of multiple cellular
and ECM layers, present in many native tubular organs, is
still to be achieved using these methods. Other techniques,
such as rod support printing, have the potential to create
tubes that are composed of multiple layers of cell-laden
hydrogel variants. Various levels of this type of cell-ECM
organisation have also been demonstrated using other tis-
sue engineering techniques, beyond 3D printing, such as
sheet rolling [31–33], dip coating [34,35] and post assem-
bly culture reorganisation [7,25,36,37]. Although extremely
promising, such methods are currently limited in terms of
the anatomical complexity that is required in many tubular
organ reconstruction scenarios. Therefore, future develop-
mental advances in tubular tissue biofabrication may reside
in combining the advantages of spatial control provided by
3D printing with the cellular scale organisation control seen
in other tissue engineering methods.
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